BAYER AG

Bayer announced FDA acceptance of its NDA for elinzanetant, a non-hormonal treatment for moderate-to-severe vasomotor symptoms associated with menopause. The NDA is supported by positive results from Phase III studies OASIS 1, 2, and 3. Elinzanetant, a dual neurokinin-1 and 3 receptor antagonist, aims to offer a new treatment option for menopausal women.

AI in drug development can reduce costs and improve clinical trial success, but challenges like data quality and regulatory acceptance remain.

Lance Yuen, new CEO of CK Life Sciences, aims to leverage his experience at Bristol-Myers Squibb and Bayer to commercialize drug candidates and boost earnings. Yuen, a 'commercialization expert,' believes in early involvement in drug development. CK Life recently merged its Wex Pharmaceuticals with Virios Therapeutics for $100 million.

Bayer and MOMA Therapeutics collaborate to develop a small molecule oncology program using MOMA’s KNOMATIC™ platform, with Bayer responsible for preclinical, development, and commercial activities. MOMA receives upfront payment, collaboration fee, and potential milestones and royalties.

The global OTC drug and dietary supplement market was valued at $310.96 billion in 2023, expected to reach $438.25 billion by 2028, and $632.1 billion by 2033. Factors driving growth include health consciousness, dietary supplement demand, government initiatives, aging population, and e-commerce expansion. Key segments include vitamin and dietary supplements, tablets, and pharmacies. North America leads the market, with Asia-Pacific and Africa expected to grow fastest.

Switch Market flag for country-specific data. Right-click for chart options. Use arrows to navigate symbols.

The drug and biotech industry thrives on M&A, new drug launches, and pipeline successes, with obesity drugs from Novo Nordisk and Eli Lilly leading. Large drugmakers like Eli Lilly, AstraZeneca, Pfizer, Sanofi, and Bayer are profitable and innovative, focusing on areas like weight loss, inflammation, and Alzheimer’s. Despite headwinds such as pipeline setbacks and macroeconomic uncertainty, investment in drug/biotech stocks has surged. The Zacks Large Cap Pharmaceuticals industry ranks in the top 19% of Zacks industries, outperforming the Zacks Medical Sector but slightly underperforming the S&P 500.

The report on the Personalized Medicine Market by Vantage Market Research highlights market size, forecast, opportunities, key drivers, regulatory scenario, industry trends, new product approvals, competitive landscape, and regional analysis. Key players include Abbott Laboratories, Merck & Co., AstraZeneca, Pfizer, GlaxoSmithKline, Novartis, Amgen, Bayer, Eli Lilly, Illumina, Danaher, QIAGEN, 23andMe, Roche, Thermo Fisher Scientific, GE Healthcare, and Precision Biologics. Market types cover diagnostics, therapeutics, medical care, and nutrition, while applications include oncology, neurology, cardiology, antiviral, psychiatry, immunology, and others. The report also examines COVID-19's impact on the market.

AI-powered Recursion Pharmaceuticals (RXRX) hit a milestone with FDA approval for REC-1245, targeting RBM39 in advanced cancers. The company plans to merge with Exscientia (EXAI) in 2025 and has partnerships with Bayer (BAYZF) and Sanofi (SNY), with an average 12-month target price of $10.14 for RXRX stock.